OPDIVO® (nivolumab)

Patient Alert Card

▼ Nivolumab is subject to additional monitoring to quickly identify new safety information. You can help by reporting any side effects that you may get to your Doctor.

This card contains important information.

Please carry this card with you at all times to inform healthcare professionals that you are receiving treatment with Opdivo or Opdivo in combination with Yervoy.

TELL YOUR DOCTOR RIGHT AWAY IF YOU HAVE ANY OF THESE SYMPTOMS OR ANY OTHER SYMPTOMS

LUNGS[1]
breathing difficulties, cough

BOWEL AND STOMACH[1]
diarrhoea (watery, loose or soft stools), blood or mucus in your stools, dark-coloured stools, pain or tenderness in your stomach or abdominal area

LIVER[1]
eye or skin yellowing (jaundice), pain on the right side of your stomach area, tiredness

KIDNEYS[1]
decreased amount of urine

DIABETES/DIABETIC KETOACIDOSIS[1]
excessive thirst, increased appetite with loss of weight, tiredness, weakness, drowsiness, depression, irritability, feeling unwell, increased amount of urine

SKIN[1]
skin reactions like skin rash with or without itching, blisters and/or peeling of the skin (possibly fatal), ulcers, dry skin, skin nodules

HORMONE-PRODUCING GLANDS[1]
headaches, blurry or double vision, fatigue (extreme tiredness), weight changes, behavioural changes (e.g. less sex drive, irritability or forgetfulness)

HEART[1]
chest pain, irregular heartbeat, palpitations

MUSCLES[1]
muscle pain, stiffness, weakness, confusion, decreased amount of urine, dark urine, severe fatigue

OTHER[1]
eye pain or redness, blurry vision, or other vision problems; upper abdominal pain, decreased appetite, nausea or vomiting; indigestion or heartburn; tingling or numbness in arms and legs, or difficulty walking; fever, swollen lymph nodes; signs or symptoms of inflammation of the brain, which may include headache, fever, seizures, stiff neck, tiredness, confusion, weakness or drowsiness

IMPORTANT

- Early management of side effects by your doctor reduces the likelihood that treatment with Opdivo (nivolumab) or Opdivo in combination with Yervoy (ipilimumab) will need to be temporarily or permanently stopped.
- Symptoms that may appear mild can quickly worsen if left untreated.[1]
- Don't try to treat these symptoms yourself.
- Report any of these symptoms or any other symptoms to your doctor right away.
- Signs and symptoms may be delayed, and may occur weeks to months after your last injection.[1]
- Carry this card with you at all times to inform healthcare professionals that you are receiving treatment with Opdivo (nivolumab) or Opdivo in combination with Yervoy (ipilimumab).

TELL YOUR DOCTOR BEFORE YOU START RECEIVING OPDIVO IF YOU:

- know you are allergic to Opdivo (nivolumab) or any other medicine or medicine ingredients
- have an autoimmune disease
- have melanoma of the eye
- have experienced side effects with another drug, such as Yervoy (ipilimumab)
- have been told cancer has spread to your brain
- have taken medicine to suppress your immune system
- have received a transplant (Opdivo may cause rejection of transplanted organs; e.g. kidney, liver, heart, cornea, or skin)
- have received a bone marrow or stem cell transplant from another person (allogeneic)
- have any history of inflammation of the lungs
- are pregnant or planning to become pregnant, or are breastfeeding
- are taking or have taken any other medicines
- are on a low salt diet

For more information, consult the Opdivo Package Leaflet included with the package, as well as on **www.fass.se** and **www.ema.europa.eu** or call Medical Information on **08-585 07 304**

Bristol-Myers Squibb

OPDIVO® (nivolumab)

Patient Alert Card

▼ Nivolumab is subject to additional monitoring to quickly identify new safety information. You can help by reporting any side effects that you may get to your Doctor.

IMPORTANT
Information for Healthcare Professionals

- This patient is treated with **Opdivo (nivolumab)** or **Opdivo in combination with Yervoy (ipilimumab)**.
- Immune-related adverse reactions (irARs) may appear at any time during treatment or months after its discontinuation.
- Early diagnosis and appropriate management are essential to minimise life-threatening complications. Opdivo-specific management guidelines for irARs are available.
- Consultation with a specialist in oncology, hematology or pulmonary medicine may be helpful for management of organ-specific irARs.

Healthcare professionals should consult the OPDIVO® Summary of Product Characteristics (SmPC) at **www.fass.se**, **www.ema.europa.eu**, link to Risk Minimisation Information for Healthcare Professionals – Guide for Prescribing and Patient Alert Card is available at Opdivo.se or call Bristol-Myers Squibb Medical Information on **08-585 07 304**.

My Doctor's Contact Information

Name of Doctor:

Office Phone:

After-Hours Phone:

My Contact Information

My Name and Phone Number:

Emergency Contact (in case of emergency):

1. OPDIVO® Package Leaflet.

NOVEMBER 2018, IO1506SE1905270

Bristol-Myers Squibb